Comparative Pharmacology
Head-to-head clinical analysis: DENTIPATCH versus LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DENTIPATCH versus LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER.
DENTIPATCH vs LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Local anesthetic agent that inhibits sodium ion influx into nerve cells, blocking nerve conduction and pain sensation.
Blocks voltage-gated sodium channels, inhibiting action potential propagation in neurons and cardiac myocytes.
Apply one 10 mg/10 cm² transdermal patch to intact skin once daily, typically in the morning; remove after 24 hours and replace with a new patch.
1-1.5 mg/kg IV bolus, then 0.5-0.75 mg/kg IV bolus every 5-10 min to a max of 3 mg/kg total loading dose; maintenance infusion 1-4 mg/min IV. For epidural: 5-10 mL of 1-2% solution.
None Documented
None Documented
Terminal elimination half-life is approximately 7–9 hours; clinically, steady-state is achieved after 2–3 days of daily application.
Terminal elimination half-life: 1.5–2 hours (single dose); prolonged to 2–3 hours with repeated dosing or in heart failure, liver disease, or elderly. Context: Effective for 1–2 hours after IV bolus, requiring infusion for sustained effect.
Approximately 60% of the dose is excreted renally as unchanged drug and metabolites; the remainder is eliminated via biliary/fecal routes.
Renal excretion of unchanged drug and metabolites: ~90% as metabolites (e.g., monoethylglycinexylidide, glycinexylidide), <10% unchanged. Biliary/fecal: minimal (<1%).
Category C
Category A/B
Local Anesthetic
Local Anesthetic / Antiarrhythmic (Class Ib)